Studies offer new evidence for possible link between blood type and COVID-19 susceptibility and severity
Two studies published today in Blood Advances suggest people with blood type O may have a lower risk of COVID-19 infection and reduced likelihood of severe outcomes, including organ complications, if they do get sick. Read more.
Read this summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic published by The Lancet Oncology. Read more.
PatientView has been researching the views and needs of patient groups worldwide and they are using their network to track the needs and actions of patient groups as they adapt to the demands of Covid-19 by collating the various communications and tweets under the hashtag #PAGC19. Read more.
New clinical trial to evaluate the myeloma drug selinexor as potential treatment for patients with COVID-19
The pharmaceutical company, Karyopharm Therapeutics has announced plans to initiate a global randomized clinical trial for low dose oral selinexor in hospitalized patients with severe COVID-19 (coronavirus). Selinexor, marketed as XPOVIO®, is currently approved at higher doses by the Food and Drug Administration (FDA) as a treatment for patients with relapsed or refractory multiple myeloma. Read more.
A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have myeloma and other blood cancers. Read more.
Myeloma Patients Europe (MPE) has put together an advice sheet for our members and myeloma patients on COVID-19 (coronavirus). This advice has been reviewed by our scientific advisors and will be continually updated to reflect the latest information. Read more.
Many WECAN member organisations are providing informational resources about COVID-19 and about specific recommendations to their patient community. Here you find links to the COVID-19 resources provided on the websites of those patient organisations, which may link to additional relevant articles and tools for their specific disease area. Read more.
Recording of the webinar held by the International Academy for Clinical Hematology (IACH) on COVID-19. The webinar was given by Prof. Mohamad Mohty and Prof. Marivi Mateos. Watch it here.
These recommendations aim to develop guidance to mitigate the negative effects of the COVID-19 pandemic on the diagnosis and treatment of myeloma patients. Read more.
The American Society of Clinical Oncology (ASCO) patient information website has regularly updated information about COVID-19 for people with cancer and cancer survivors in English and Spanish. Read more.
The European Society for Medical Oncology (ESMO) is supporting oncology professionals by gathering information and resources on COVID-19 Read more.
Read here the latest information provided by the World Health Organisation (WHO) regarding COVID-19. Read more.
At this crucial stage, efforts are being devoted by different initiatives for the generation of documents with indications for the clinical care of these patients. Find here some of the documents produced with the participation of EuroBloodNet members, including language and target (health professionals or patients). Read more.
The United States and countries around the world face a major public health concern with the current outbreak of the novel COVID-19. In an effort to serve its members, ASH is maintaining this webpage as a medium to exchange information to assist hematologists in navigating the COVID-19 public health crisis. Read more.
In view of the rapidly changing evidence and general situation the EHA Scientific Working Group Infections in Hematology has developed key questions and answers on the management of cancer patients with or at risk of COVID-19. Read more.